KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
– Phase 2 data for KVD900 in late-breaking session at
“HAE patients continue to seek an oral option for on-demand treatment of their disease, to fully manage their disease or for breakthrough attacks for those on prophylaxis,” said Dr. Emel Aygören-Pürsün, Principal Investigator for the KVD900 Phase 2 Clinical Trial and Head of the HAE Center at the University Hospital Frankfurt. “As KVD900 halted attack progression and resolved attacks more quickly in patients with HAE, while demonstrating a good safety and tolerability profile, it could be a valued choice for physicians and patients in managing HAE.”
The late-breaking poster, titled A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): results of a phase 2, placebo-controlled, double-blind cross-over trial, contains the comprehensive data set from the company’s Phase 2 clinical trial of KVD900 in HAE patients. The presented data supports the topline results reported in
- Early use of KVD900 halted attack progression.
- Use of KVD900 significantly shortened the time to improvement of attack symptoms.
- KVD900 accelerated attack resolution.
- KVD900 was generally safe and well tolerated in the study.
Poster Title: Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-
- While patients with nC1-HAE require similar care to those with C1INH-HAE (type I and II), the population prevalence of this condition is unknown.
This study aimed to estimate the prevalence of nC1-
HAE inthe U.S.based on physician-level prescription data and responses to an internet-based survey which yielded 113 survey responses.
- Respondents were required to have seen at least 5 HAE patients in the prior 12 months and treated at least 1 nC1-HAE patient in that timeframe.
- The estimated prevalence for nC1-HAE was 0.44 per 100,000, accounting for up to 16.4%-22.7% of the total HAE population.
Patients with nC1-HAE may represent a more sizeable population of patients with
HAE inthe U.S.than previously suspected.
Poster Title: Current management of hereditary angioedema with normal C1-inhibitor (nC1-
- Robust study data are lacking on the management of patients with nC1-HAE.
- The study included a 10-minute online survey of specialist practices managing HAE who commonly evaluate and treat patients with HAE and nC1-HAE.
- Patients are currently managed and treated with medications studied in patients with HAE types I and II, with icatibant being the most commonly used treatment for acute attacks and lanadelumab most preferred for prophylaxis.
- The highest-ranked unmet need in acute treatment and preventative care was for an oral, FDA-approved, nC1-HAE-specific treatment.
Poster Title: Oral plasma kallikrein inhibitor KV998052 improves arterial blood oxygenation in a murine model of acute respiratory distress syndrome (ARDS)
- Recent data from published sources support the association of kallikrein-kinin activation and bradykinin generationwith SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
- Pretreatment of mice with orally administered KV998052 was associated with significantly improved blood oxygenation in mice with HCI induced ARDS compared with mice receiving vehicle.
- Pharmacological inhibition of plasma kallikrein (PKa) provides a therapeutic opportunity to improve arterial blood oxygenation in ARDS.
Poster Title: Selective oral Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogen
- In the study, FactorXII knockout mice were fully protected against captopril-induced leakage.
- KV998083 achieved protection of kininogen (HK) in plasma.
- These preclinical results suggest that Factor XIIa inhibition may prevent bradykinin-induced angioedema.
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the